OraSure Investor Relations Material
OraSure Technologies, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices for testing for the presence of Hepatitis B surface antigen, human immunodeficiency virus type 1/2, antibiotic-resistant Neisseria gonorrhoeae resistance to antibiotics, human papillomavirus genotypes 16 and 18 in women aged 23 to 65 years are at increased risk of cervical cancer, discrimination based on drug abuse or HIV status; sexually transmitted infections; or male infertility. The company offers single use kits that are designed to evaluate oral fluid specimens collected using cheek swab samples; oral fluid collection device allowing collection of saliva specimens without venipuncture; OraQuick HIV-1/2 SureView test for qualitative detection of antigens and antibodies against HIV-1 and HIV-2
Key slides for OraSure Technologies Inc
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
🇺🇸 United States